Grace Therapeutics, Inc GRCE

Healthcare Biotechnology

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.

NDAQ:GRCE - Post by User

Grace Therapeutics, Inc

Bullboard Posts

Comment by wobbleson May 25, 2020 2:47am

208 Views

Post# 31067716

RE:RE:Be very careful

To be honest, I hope that Acasti are the ones being very careful. Perhaps those old dogs can learn new tricks.
I already made my bed investing in ACST, and I am lying in it.

Biotech is a roller coaster, and in this particular ACST case I truly can't get off....not yet.
I am waiting for my exit point. No panic (I'm not built that way, thankfully) but senses working overtime as the clock ticks.

Bullboard Posts

Anaergia expands relationship with PepsiCo